How Long Does It Take to Feel the Effects of Wegovy?

What the STEP 1 trial data says about early versus sustained effects

The clearest picture of how long Wegovy's effects take to establish comes from the STEP 1 trial, published in the New England Journal of Medicine. In that study, adults with obesity took semaglutide 2.4mg once weekly for 68 weeks alongside lifestyle support. Average body weight fell by around 15% over that period. Crucially, the data show a gradual, sustained reduction rather than a sudden drop: the appetite-suppressing effect of semaglutide begins early, but the weight-loss curve steepens as the dose increases and the body adapts over weeks and months.

Early on, the 0.25mg starting dose is a tolerability step. Its job is to let your digestive system adjust, not to produce the headline results. Participants typically noticed appetite shifts within the first month, but the bigger reductions in food intake, and the measurable changes on the scale, tracked with each upward dose step. By weeks 12 to 20, once most patients had reached 1.7mg or 2.4mg, the curve became steeper. The full effect of the maintenance dose continues to compound beyond that.

If you are curious how this compares with semaglutide more broadly, our overview of semaglutide's timeline covers the shared mechanisms across formulations.

The first few weeks: what people actually notice, and what they do not

A question our prescribers hear most weeks is: "I've had my first injection, why don't I feel different yet?" The honest answer is that the first pen is not meant to produce dramatic hunger suppression. Semaglutide slows gastric emptying and acts on GLP-1 receptors in the brain's appetite centres, but at 0.25mg these effects are mild. If you want to understand how quickly you can expect to feel the effects of Wegovy, our dedicated page walks through what happens at each stage of the titration. The most common early experiences are not weight loss but subtle shifts, feeling full sooner mid-meal, losing interest in food slightly earlier in the evening, or noticing that a smaller portion leaves you satisfied.

Nausea is also common in the first few weeks, particularly after a dose increase. For most people it is mild and settles within days; it is not a sign that the medicine is harming you, but it can be mistaken for the medicine "not working". The NHS semaglutide page outlines what to expect and which symptoms need prompt medical attention. If side effects are a concern before you start, the frequently asked questions on our site address the most common ones.

The pen itself arrives in plain, unbranded packaging via DPD with a tracked delivery link (easy to manage discreetly) and it needs to go straight into the fridge at 2–8°C as directed in the Patient Information Leaflet.

When most people notice meaningful weight loss, and what affects the pace

For the majority of people in clinical trials, a noticeable and sustained reduction in body weight became apparent between weeks six and sixteen. By that point, most patients had moved through at least one or two dose increases, and the cumulative effect of reduced appetite, slower gastric emptying, and improved satiety signalling was producing consistent weekly deficits.

Several factors influence pace. Dose reached matters most: patients who tolerate the titration to 2.4mg see the strongest outcomes. Diet quality alongside treatment, protein intake in particular, affects how much of the weight lost comes from fat rather than lean mass. Activity level plays a supporting role. And starting BMI can influence the rate of early change, people with a higher starting weight often see larger absolute reductions in the early months, though percentage outcomes converge over time.

For a closer look at how quickly the first effects appear, that page goes into the early-week experience in more detail. Understanding what shapes the individual timeline can also help set realistic expectations before starting.

One practical note: if you are considering private treatment and want to understand what is included in the cost, our treatment overview explains the full picture, including what is covered in a single transparent price.

After six months: reviewing progress and what comes next

NICE guidance on semaglutide (Wegovy) recommends reviewing progress after six months at the maintenance dose. If body weight has not fallen by at least 5% by that point, continuing treatment should be discussed with your prescriber. This is not a cut-off most people hit (the STEP 1 data show the vast majority of patients achieving meaningful loss well before six months at 2.4mg) but it is a clinically important checkpoint.

Beyond six months, weight loss typically plateaus as the body finds a new setpoint. Some patients stabilise at a lower weight and maintain it; others see continued gradual reduction. Both outcomes are described in the long-term extension data. What the evidence firmly supports is that stopping Wegovy abruptly, without a plan for what comes next, is associated with weight returning. That is a conversation worth having with your prescriber before you start, not after.

The Wegovy treatment page covers the licensed indications, dosing schedule, and what clinical support looks like at each stage. If you are ready to speak with a prescriber and check whether you are suitable, you can check your eligibility with a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.